Showing results (71-80 of 340) with videos related to

Sort By:
Pageof 34
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 6, 2022
Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular CarcinomaYu-Han Huang, Chi Chan, Hye-Won Lee, et al.
Hepatology International|February 3, 2011
Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in TaiwanJeng-Fu Yang, Yi-Hui Kao, Chia-Yen Dai, et al.
Journal of Hepatology|February 24, 2009
Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patientsChia-Yen Dai, Jee-Fu Huang, Ming-Yen Hsieh, et al.
Plos One|November 6, 2018
Association of hyperuricemia with disease severity in chronic hepatitis C patientsTyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, et al.
Plos One|April 4, 2015
Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patientsMing-Lun Yeh, Cheng-Yuan Peng, Chia-Yen Dai, et al.
Hepatology International|November 15, 2018
Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antiviralsChung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, et al.
Hepatology International|July 24, 2015
Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremicsChung-Feng Huang, Ming-Lun Yeh, Jia-Jung Lee, et al.
The Kaohsiung Journal of Medical Sciences|November 17, 2016
Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter studyMing-Lun Yeh, Ching-I Huang, Ming-Yen Hsieh, et al.
International Journal of Medical Sciences|April 2, 2014
Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patientsJer-Ming Chang, Chung-Feng Huang, Szu-Chia Chen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|September 9, 2022
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinomaZu-Yau Lin, Ming-Lun Yeh, Ching-I Huang, et al.
Pageof 34